KR102173464B9 - 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 - Google Patents
에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체Info
- Publication number
- KR102173464B9 KR102173464B9 KR1020207004766A KR20207004766A KR102173464B9 KR 102173464 B9 KR102173464 B9 KR 102173464B9 KR 1020207004766 A KR1020207004766 A KR 1020207004766A KR 20207004766 A KR20207004766 A KR 20207004766A KR 102173464 B9 KR102173464 B9 KR 102173464B9
- Authority
- KR
- South Korea
- Prior art keywords
- tetrahydronaphthalene
- estrogen receptor
- tetrahydroisoquinoline derivatives
- receptor degraders
- degraders
- Prior art date
Links
- 229940125641 estrogen receptor degrader Drugs 0.000 title 1
- 125000003039 tetrahydroisoquinolinyl group Chemical class C1(NCCC2=CC=CC=C12)* 0.000 title 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662429041P | 2016-12-01 | 2016-12-01 | |
US62/429,041 | 2016-12-01 | ||
US201762540049P | 2017-08-01 | 2017-08-01 | |
US62/540,049 | 2017-08-01 | ||
KR1020197019065A KR102674902B1 (ko) | 2016-12-01 | 2017-12-01 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020197019065A Division KR102674902B1 (ko) | 2016-12-01 | 2017-12-01 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
Publications (3)
Publication Number | Publication Date |
---|---|
KR20200020988A KR20200020988A (ko) | 2020-02-26 |
KR102173464B1 KR102173464B1 (ko) | 2020-11-04 |
KR102173464B9 true KR102173464B9 (ko) | 2022-05-23 |
Family
ID=62240410
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020197019065A KR102674902B1 (ko) | 2016-12-01 | 2017-12-01 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
KR1020247014021A KR20240063185A (ko) | 2016-12-01 | 2017-12-01 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
KR1020207004766A KR102173464B1 (ko) | 2016-12-01 | 2017-12-01 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020197019065A KR102674902B1 (ko) | 2016-12-01 | 2017-12-01 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
KR1020247014021A KR20240063185A (ko) | 2016-12-01 | 2017-12-01 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
Country Status (23)
Country | Link |
---|---|
US (6) | US10647698B2 (ko) |
EP (2) | EP3548483A4 (ko) |
JP (5) | JP6957620B2 (ko) |
KR (3) | KR102674902B1 (ko) |
CN (3) | CN110291087B (ko) |
AU (5) | AU2017366693B2 (ko) |
BR (1) | BR112019011200B1 (ko) |
CA (1) | CA3042968C (ko) |
CO (1) | CO2019007091A2 (ko) |
DK (1) | DK3689868T3 (ko) |
ES (1) | ES2967404T3 (ko) |
FI (1) | FI3689868T3 (ko) |
HR (1) | HRP20231537T1 (ko) |
HU (1) | HUE064609T2 (ko) |
IL (4) | IL266842B (ko) |
LT (1) | LT3689868T (ko) |
MX (2) | MX2019006402A (ko) |
PL (1) | PL3689868T3 (ko) |
PT (1) | PT3689868T (ko) |
RS (1) | RS64976B1 (ko) |
RU (1) | RU2750484C2 (ko) |
SI (1) | SI3689868T1 (ko) |
WO (1) | WO2018102725A1 (ko) |
Families Citing this family (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220029783A (ko) | 2015-01-20 | 2022-03-08 | 아비나스 오퍼레이션스, 인코포레이티드 | 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법 |
US20170327469A1 (en) | 2015-01-20 | 2017-11-16 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
EP3302482A4 (en) | 2015-06-05 | 2018-12-19 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
WO2017030814A1 (en) | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
EP3512842B1 (en) | 2016-09-15 | 2024-01-17 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
US10683387B2 (en) | 2016-10-04 | 2020-06-16 | Massachusetts Institute Of Technology | Bottlebrush copolymers and uses thereof |
AU2017367872B2 (en) | 2016-11-01 | 2022-03-31 | Arvinas, Inc. | Tau-protein targeting protacs and associated methods of use |
RU2750484C2 (ru) | 2016-12-01 | 2021-06-28 | Эрвинэс Оперейшнс, Инк. | Производные тетрагидронафталина и тетрагидроизохинолина в качестве разрушителей эстрогенового рецептора |
EP3559006A4 (en) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES |
US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
WO2018119448A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
CA3047586A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas Operations, Inc. | Egfr proteolysis targeting chimeric molecules and associated methods of use |
US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
KR20230140606A (ko) | 2017-01-26 | 2023-10-06 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 단백질 분해 조절제 및 관련 사용 방법 |
CN118440096A (zh) | 2017-06-20 | 2024-08-06 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
EP3679027A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Dihydrobenzimidazolones |
WO2019043208A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROQUINOLINONES |
CN111278815B (zh) | 2017-09-04 | 2024-03-08 | C4医药公司 | 戊二酰亚胺 |
WO2019099868A2 (en) | 2017-11-16 | 2019-05-23 | C4 Therapeutics, Inc. | Degraders and degrons for targeted protein degradation |
WO2019099926A1 (en) | 2017-11-17 | 2019-05-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
WO2019148055A1 (en) | 2018-01-26 | 2019-08-01 | Yale University | Imide-based modulators of proteolysis and methods of use |
CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
KR20230130752A (ko) | 2018-04-04 | 2023-09-12 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해 조절제 및 연관된 사용 방법 |
CN110357889B (zh) * | 2018-04-09 | 2022-03-15 | 上海科技大学 | 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用 |
IL302595A (en) * | 2018-04-13 | 2023-07-01 | Arvinas Operations Inc | Servalon ligands and bifunctional compounds containing them |
CN112312904A (zh) | 2018-04-16 | 2021-02-02 | C4医药公司 | 螺环化合物 |
DK3784663T3 (da) | 2018-04-23 | 2023-10-16 | Celgene Corp | Substituerede 4-aminoisoindolin-1,3-dionforbindelser og deres anvendelse til behandlng af et lymfom |
EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
BR122022012697B1 (pt) | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
AR116109A1 (es) * | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
US11639354B2 (en) | 2018-07-31 | 2023-05-02 | Fimecs, Inc. | Heterocyclic compound |
WO2020041331A1 (en) | 2018-08-20 | 2020-02-27 | Arvinas Operations, Inc. | Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases |
WO2020051235A1 (en) | 2018-09-04 | 2020-03-12 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
CN113164409B (zh) * | 2018-11-21 | 2023-07-18 | 冰洲石生物科技公司 | 具有雌激素受体α降解活性的化合物及其用途 |
US20240245670A1 (en) * | 2018-12-20 | 2024-07-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
JP2022515890A (ja) * | 2019-01-03 | 2022-02-22 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | エストロゲン受容体タンパク質分解薬 |
BR112021015672A2 (pt) * | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos |
EP3924054A1 (en) | 2019-02-15 | 2021-12-22 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
CN113747925A (zh) | 2019-03-21 | 2021-12-03 | 科迪亚克生物科学公司 | 胞外囊泡缀合物及其用途 |
WO2020191369A1 (en) | 2019-03-21 | 2020-09-24 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
TW202102497A (zh) | 2019-03-29 | 2021-01-16 | 瑞典商阿斯特捷利康公司 | 化合物及它們在治療癌症中之用途 |
US20220241424A1 (en) | 2019-04-16 | 2022-08-04 | Northwestern University | Treatment of cancer |
US20220220124A1 (en) * | 2019-04-18 | 2022-07-14 | Accutar Biotechnology Inc. | Novel compounds having bet, estrogen receptor, and androgen receptor degradation activity and uses thereof |
CN114867727A (zh) | 2019-07-17 | 2022-08-05 | 阿尔维纳斯运营股份有限公司 | Tau蛋白靶向化合物及相关使用方法 |
WO2021018118A1 (en) * | 2019-07-29 | 2021-02-04 | Janssen Pharmaceutica Nv | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 1 proteins |
JP2022546471A (ja) | 2019-08-26 | 2022-11-04 | アルビナス・オペレーションズ・インコーポレイテッド | エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体を用いて乳癌を治療する方法 |
JP7307796B2 (ja) * | 2019-09-23 | 2023-07-12 | アキュター バイオテクノロジー インコーポレイテッド | アンドロゲン受容体分解活性を有する新規の置換キノリン-8-カルボニトリル誘導体およびその使用 |
CN112574278B (zh) * | 2019-09-29 | 2024-08-23 | 江西济民可信集团有限公司 | 作为蛋白降解剂杂环类化合物及其制备方法和医药应用 |
TWI836159B (zh) | 2019-11-19 | 2024-03-21 | 美商必治妥美雅史谷比公司 | 可作為helios蛋白質抑制劑之化合物 |
EP4069228A4 (en) * | 2019-12-06 | 2024-04-17 | Celgene Corporation | PROCESS FOR PREPARING 2-(4-CHLORPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUORACETAMIDE |
DK3835298T3 (da) * | 2019-12-12 | 2024-07-29 | Accutar Biotechnology Inc | Nye chromanderivater med østrogenreceptornedbrydende aktivitet og anvendelser heraf |
EP4076464A4 (en) * | 2019-12-17 | 2024-06-12 | Orionis Biosciences, Inc. | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION |
BR112022011796A2 (pt) | 2019-12-18 | 2022-08-30 | Novartis Ag | Derivados de 3-(5-metóxi-1- oxoisoindolin-2-il)piperidina-2,6-diona e usos dos mesmos |
MX2022007678A (es) | 2019-12-19 | 2022-09-19 | Arvinas Operations Inc | Compuestos y metodos para la degradacion dirigida del receptor de androgenos. |
JP2023508357A (ja) * | 2019-12-23 | 2023-03-02 | アキュター バイオテクノロジー インコーポレイテッド | エストロゲン受容体分解剤とサイクリン依存性キナーゼ阻害剤との癌治療用組み合わせ |
US12042513B2 (en) * | 2020-01-10 | 2024-07-23 | Massachusetts Institute Of Technology | Proteolysis targeting chimeric molecules (PROTACs) with functional handles and uses thereof |
JP2023512040A (ja) * | 2020-01-29 | 2023-03-23 | フォグホーン セラピューティクス インコーポレイテッド | 化合物及びその使用 |
WO2021170021A1 (zh) * | 2020-02-25 | 2021-09-02 | 上海科技大学 | 基于戊二酰亚胺骨架的化合物及其应用 |
TW202140441A (zh) * | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
CN111393409A (zh) * | 2020-03-27 | 2020-07-10 | 苏州昊帆生物股份有限公司 | 蛋白降解靶向嵌合体化合物、应用及其制备方法 |
WO2021237100A1 (en) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
PE20231555A1 (es) * | 2020-09-14 | 2023-10-03 | Arvinas Operations Inc | Formas cristalinas y amorfas de un compuesto para la degradacion dirigida del receptor de estrogenos |
CN112094275A (zh) * | 2020-09-16 | 2020-12-18 | 迪嘉药业集团有限公司 | 一种(右)佐匹克隆光降解杂质的制备方法 |
US20240241020A1 (en) | 2020-09-23 | 2024-07-18 | Lonza Sales Ag | Process for preparing extracellular vesicles |
IL302669A (en) | 2020-11-06 | 2023-07-01 | Prelude Therapeutics Inc | BRM-targeted compounds and related methods of use |
KR20230121801A (ko) * | 2020-12-14 | 2023-08-21 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌유도체로 유방암을 치료하는 방법 |
MX2023008296A (es) | 2021-01-13 | 2023-09-29 | Monte Rosa Therapeutics Inc | Compuestos de isoindolinona. |
CN116438177A (zh) * | 2021-01-28 | 2023-07-14 | 江苏亚虹医药科技股份有限公司 | 靶向嵌合化合物、含其的药物组合物及其制备方法和用途 |
EP4289841A1 (en) * | 2021-02-04 | 2023-12-13 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Benzo seven-membered ring bifunctional compound and application thereof |
CA3211378A1 (en) * | 2021-03-29 | 2022-10-06 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Tetrahydronaphthalene compound, and preparation method therefor and use thereof in medicine |
IL307338A (en) | 2021-04-05 | 2023-11-01 | Bristol Myers Squibb Co | Pyridinyl substituted oxisoisoindoline compounds for cancer therapy |
JP2024515243A (ja) | 2021-04-06 | 2024-04-08 | ブリストル-マイヤーズ スクイブ カンパニー | ピリジニル置換されたオキソイソインドリン化合物 |
AU2022259683A1 (en) | 2021-04-16 | 2023-10-19 | Arvinas Operations, Inc. | Modulators of bcl6 proteolysis and associated methods of use |
EP4334302A1 (en) * | 2021-05-03 | 2024-03-13 | Nurix Therapeutics, Inc. | Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use |
US20240287076A1 (en) | 2021-05-05 | 2024-08-29 | Biogen Ma Inc. | Compounds for targeting degradation of bruton's tyrosine kinase |
AR126052A1 (es) * | 2021-06-03 | 2023-09-06 | Novartis Ag | Derivados de 3-(5-oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos |
EP4367113A1 (en) | 2021-07-07 | 2024-05-15 | Biogen MA Inc. | Compounds for targeting degradation of irak4 proteins |
EP4366834A1 (en) | 2021-07-07 | 2024-05-15 | Biogen MA Inc. | Compounds for targeting degradation of irak4 proteins |
CN117715889A (zh) | 2021-07-26 | 2024-03-15 | 阿尔维纳斯运营股份有限公司 | 制备双官能化合物的方法 |
EP4421071A1 (en) * | 2021-10-22 | 2024-08-28 | Gluetacs Therapeutics (Shanghai) Co., Ltd. | Crbn e3 ligase ligand compound, protein degrading agent developed on the basis of ligand compound, and their applications |
CA3237756A1 (en) | 2021-11-09 | 2023-05-19 | Hangzhou Glubio Pharmaceutical Co., Ltd. | Wee1 protein kinase degradation agent and use thereof |
WO2023116835A1 (zh) * | 2021-12-24 | 2023-06-29 | 苏州开拓药业股份有限公司 | 一种具有酰亚胺骨架的多蛋白降解剂 |
CN114085213B (zh) * | 2022-01-20 | 2022-03-25 | 苏州国匡医药科技有限公司 | 一种arv-471的制备方法 |
US20230373950A1 (en) | 2022-03-17 | 2023-11-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
CN117229286A (zh) * | 2022-06-14 | 2023-12-15 | 海创药业股份有限公司 | 一种芳香类化合物及其制备方法及在制备雌激素受体降解剂中的用途 |
WO2023242598A1 (en) * | 2022-06-16 | 2023-12-21 | Amphista Therapeutics Limited | Bifunctional molecules for targeted protein degradation |
WO2024006776A1 (en) * | 2022-06-27 | 2024-01-04 | Relay Therapeutics, Inc. | Estrogen receptor alpha degraders and medical use thereof |
TW202417425A (zh) * | 2022-06-27 | 2024-05-01 | 美商傳達治療有限公司 | 雌激素受體α降解劑及其使用方法 |
US20240067632A1 (en) * | 2022-06-30 | 2024-02-29 | Bristol-Myers Squibb Company | WEE1 Degrading Compounds and Uses Thereof |
WO2024015412A1 (en) * | 2022-07-12 | 2024-01-18 | Regents Of The University Of Michigan | Tetrahydronaphthalene derivatives as estrogen receptor degraders |
WO2024049926A1 (en) | 2022-08-31 | 2024-03-07 | Arvinas Operations, Inc. | Dosage regimens of estrogen receptor degraders |
TW202416992A (zh) | 2022-08-31 | 2024-05-01 | 美商亞文納營運公司 | 雌激素受體降解劑之給藥方案 |
WO2024054591A1 (en) | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
US20240158370A1 (en) * | 2022-09-09 | 2024-05-16 | Innovo Therapeutics, Inc. | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS |
WO2024073507A1 (en) | 2022-09-28 | 2024-04-04 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
WO2024067781A1 (zh) * | 2022-09-29 | 2024-04-04 | 江苏恒瑞医药股份有限公司 | 一种四氢萘类衍生物的可药用盐、晶型及制备方法 |
WO2024083716A1 (en) | 2022-10-17 | 2024-04-25 | Astrazeneca Ab | Combinations of a serd for the treatment of cancer |
US20240180893A1 (en) | 2022-11-17 | 2024-06-06 | Astrazeneca Ab | Methods of treatment of breast cancer |
KR20240078553A (ko) * | 2022-11-25 | 2024-06-04 | 재단법인 대구경북첨단의료산업진흥재단 | 선택적 에스트로겐 수용체 조절제로서의 신규 화합물 |
WO2024119081A1 (en) | 2022-12-02 | 2024-06-06 | Arvinas Operations, Inc. | Method of treating breast cancer |
CN116751186A (zh) * | 2022-12-23 | 2023-09-15 | 南京知和医药科技有限公司 | 一种雌激素受体调节剂的制备及其用途 |
CN118556048A (zh) * | 2022-12-27 | 2024-08-27 | 标新生物医药科技(上海)有限公司 | 基于硫/氧取代戊二酰亚胺基异吲哚啉酮骨架的化合物及其应用 |
WO2024141052A1 (zh) * | 2022-12-30 | 2024-07-04 | 江苏威凯尔医药科技有限公司 | 雌激素受体调节剂及其用途 |
WO2024167904A1 (en) | 2023-02-07 | 2024-08-15 | Arvinas Operations, Inc. | Dosage regimens of estrogen receptor degraders in combination with an mtor inhibitor |
Family Cites Families (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
US5510357A (en) | 1995-02-28 | 1996-04-23 | Eli Lilly And Company | Benzothiophene compounds as anti-estrogenic agents |
CA2624949C (en) | 1996-07-24 | 2011-02-15 | Celgene Corporation | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing tnf.alpha. levels |
US5916916A (en) * | 1996-10-10 | 1999-06-29 | Eli Lilly And Company | 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods |
ZA982877B (en) | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment of central nervous system disorders with selective estrogen receptor modulators. |
CA2287387C (en) | 1997-05-14 | 2010-02-16 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for destruction of selected proteins |
WO1999015521A1 (en) | 1997-09-23 | 1999-04-01 | Eli Lilly And Company | Benzothiophenes |
ES2220005T3 (es) * | 1998-06-16 | 2004-12-01 | Pfizer Products Inc. | Combinaciones terapeuticas que comprenden un modulador selectivo del receptor de estrogeno y prostaglandina e2. |
US6306663B1 (en) | 1999-02-12 | 2001-10-23 | Proteinex, Inc. | Controlling protein levels in eucaryotic organisms |
AU769652B2 (en) | 1999-05-05 | 2004-01-29 | Cubist Pharmaceuticals, Inc. | Novel prolines as antimicrobial agents |
US7208157B2 (en) | 2000-09-08 | 2007-04-24 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
EP1322750A4 (en) | 2000-09-08 | 2004-09-29 | California Inst Of Techn | PROTEOLYSIC CHIMERAL PHARMACEUTICAL |
US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
CN1264858C (zh) | 2001-02-16 | 2006-07-19 | 纳幕尔杜邦公司 | 血管生成抑制三肽、组合物及其使用方法 |
HN2002000136A (es) | 2001-06-11 | 2003-07-31 | Basf Ag | Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis |
US7030141B2 (en) | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
US20060128632A1 (en) | 2002-07-02 | 2006-06-15 | Sharma Sushil K | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
WO2005007621A2 (en) | 2003-05-30 | 2005-01-27 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
JP2007522116A (ja) | 2004-01-16 | 2007-08-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | コンホメーションが制約されたSmac模倣物およびその使用 |
JP5122275B2 (ja) | 2004-03-23 | 2013-01-16 | ジェネンテック, インコーポレイテッド | Iapのアザビシクロ−オクタンインヒビター |
EP1735307B1 (en) | 2004-04-07 | 2012-08-29 | Novartis AG | Inhibitors of iap |
RU2401840C2 (ru) | 2004-07-02 | 2010-10-20 | Дженентек, Инк. | Ингибиторы iap |
US20060167066A1 (en) | 2004-12-20 | 2006-07-27 | Genentech, Inc. | Pyrrolidine inhibitors of IAP |
TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
AU2006216450C1 (en) | 2005-02-25 | 2013-01-10 | Medivir Ab | Dimeric IAP inhibitors |
CN100383139C (zh) | 2005-04-07 | 2008-04-23 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的哌啶-2,6-二酮衍生物 |
US20060252698A1 (en) | 2005-04-20 | 2006-11-09 | Malcolm Bruce A | Compounds for inhibiting cathepsin activity |
MX2008002765A (es) | 2005-08-31 | 2008-04-07 | Celgene Corp | Compuestos de isoindol-imida y composiciones que la comprenden y metodos para usar los mismos. |
MX2008011128A (es) | 2006-03-03 | 2008-09-08 | Novartis Ag | Compuestos de n-formil-hidroxilamina. |
WO2007101347A1 (en) | 2006-03-07 | 2007-09-13 | Aegera Therapeutics Inc. | Bir domain binding compounds |
BRPI0711326B8 (pt) | 2006-05-05 | 2021-05-25 | Univ Michigan Regents | compostos miméticos de smac bivalentes |
AU2007275415A1 (en) | 2006-07-20 | 2008-01-24 | Ligand Pharmaceuticals Incorporated | Proline urea CCR1 antagonists for the treatment of autoimmune diseases or inflammation |
WO2008014236A1 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
EP2057143B1 (en) | 2006-08-30 | 2013-07-24 | Celgene Corporation | 5-substituted isoindoline compounds |
RU2448101C2 (ru) | 2006-08-30 | 2012-04-20 | Селджин Корпорейшн | 5-замещенные изоиндолиновые соединения |
EP2089391B1 (en) | 2006-11-03 | 2013-01-16 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
WO2008109057A1 (en) | 2007-03-02 | 2008-09-12 | Dana-Farber Cancer Institute, Inc. | Organic compounds and their uses |
BRPI0810178A2 (pt) | 2007-04-12 | 2014-09-23 | Joyant Pharmaceuticals Inc | Dímeros e trímeros miméticos de smac úteis como agentes anticâncer |
JP5416089B2 (ja) | 2007-04-13 | 2014-02-12 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ジアゾ二環式smac模倣物およびその使用 |
TWI432212B (zh) | 2007-04-30 | 2014-04-01 | Genentech Inc | Iap抑制劑 |
US20100203012A1 (en) | 2007-05-30 | 2010-08-12 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
KR20100032886A (ko) * | 2007-06-08 | 2010-03-26 | 아보트 러보러터리즈 | 키나제 억제제로서의 5-헤테로아릴 치환된 인다졸 |
KR20100038108A (ko) | 2007-07-25 | 2010-04-12 | 브리스톨-마이어스 스큅 컴퍼니 | 트리아진 키나제 억제제 |
EP2058312A1 (en) | 2007-11-09 | 2009-05-13 | Universita' degli Studi di Milano | SMAC mimetic compounds as apoptosis inducers |
PT2358697E (pt) | 2008-10-29 | 2016-02-03 | Celgene Corp | Compostos de isoindolina para utilização no tratamento do cancro |
US8084620B2 (en) | 2008-12-19 | 2011-12-27 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
US8063102B2 (en) * | 2009-03-13 | 2011-11-22 | N.V. Organon | Tetrahydronaphthalen-2-ol derivatives |
US20120135089A1 (en) | 2009-03-17 | 2012-05-31 | Stockwell Brent R | E3 ligase inhibitors |
US8614201B2 (en) | 2009-06-05 | 2013-12-24 | Janssen Pharmaceutica Nv | Heterocyclic amides as modulators of TRPA1 |
AU2010273220B2 (en) | 2009-07-13 | 2015-10-15 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
CN102958928B (zh) | 2009-10-28 | 2015-05-13 | 焦阳特制药股份有限公司 | 二聚体smac模拟物 |
US8440693B2 (en) * | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
NZ601289A (en) | 2010-02-11 | 2014-10-31 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
WO2012003281A2 (en) | 2010-06-30 | 2012-01-05 | Brandeis University | Small-molecule-targeted protein degradation |
CA2811567C (en) | 2010-09-24 | 2019-09-10 | The Regents Of The University Of Michigan | Deubiquitinase inhibitors and methods for use of the same |
CN102477033A (zh) | 2010-11-23 | 2012-05-30 | 苏州波锐生物医药科技有限公司 | 苯并噻酚类化合物及其在制备预防和/或治疗乳腺癌骨质疏松症药物中的用途 |
CN102477017A (zh) * | 2010-11-23 | 2012-05-30 | 苏州波锐生物医药科技有限公司 | 四氢萘衍生物及其在制备预防和/或治疗乳腺癌骨质疏松症药物中的用途 |
AU2011338615B2 (en) | 2010-12-07 | 2017-07-27 | Yale University | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same |
WO2012090104A1 (en) | 2010-12-31 | 2012-07-05 | Kareus Therapeutics, Sa | Methods and compositions for designing novel conjugate therapeutics |
US8889684B2 (en) | 2011-02-02 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
CA2834535A1 (en) | 2011-04-29 | 2012-11-01 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
JP6093770B2 (ja) | 2011-09-27 | 2017-03-08 | アムジエン・インコーポレーテツド | 癌の治療のためのmdm2阻害剤としての複素環化合物 |
WO2013071039A1 (en) | 2011-11-09 | 2013-05-16 | Ensemble Therapeutics | Macrocyclic compounds for inhibition of inhibitors of apoptosis |
EP2776409B1 (en) | 2011-11-09 | 2016-02-03 | Ensemble Therapeutics Corporation | Macrocyclic compounds for inhibition of inhibitors of apoptosis |
CN103159736B (zh) | 2011-12-10 | 2015-05-13 | 通化济达医药有限公司 | 取代的吡唑激酶抑制剂 |
DK2797888T3 (en) | 2011-12-31 | 2016-09-19 | Beigene Ltd | Fused tricyclic compounds as RAF kinase inhibitors |
RU2666530C2 (ru) * | 2012-01-12 | 2018-09-11 | Йейл Юниверсити | Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы |
WO2013106646A2 (en) | 2012-01-12 | 2013-07-18 | Yale University | Compounds and methods for the inhibition of vcb e3 ubiquitin ligase |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
EP2846784A4 (en) | 2012-05-11 | 2016-03-09 | Univ Yale | COMPOUNDS USEFUL FOR STIMULATING PROTEIN DEGRADATION AND METHODS USING THE SAME |
JP6171003B2 (ja) | 2012-05-24 | 2017-07-26 | ノバルティス アーゲー | ピロロピロリジノン化合物 |
JP6067108B2 (ja) | 2012-05-30 | 2017-01-25 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 置換ピロリジン−2−カルボキサミド |
US9345740B2 (en) | 2012-07-10 | 2016-05-24 | Bristol-Myers Squibb Company | IAP antagonists |
PL2880447T3 (pl) | 2012-07-31 | 2019-10-31 | Novartis Ag | Markery związane z wrażliwością na inhibitory ludzkiego białka „double minute " 2 (mdm2) |
WO2014025759A1 (en) | 2012-08-09 | 2014-02-13 | Bristol-Myers Squibb Company | Iap antagonists |
TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
EP2897949B1 (en) | 2012-09-18 | 2018-01-10 | Bristol-Myers Squibb Company | Iap antagonists |
EP2903998B1 (en) | 2012-10-02 | 2017-03-15 | Bristol-Myers Squibb Company | Iap antagonists |
CA2930030A1 (en) | 2012-11-09 | 2014-05-15 | Ensemble Therapeutics Corporation | Macrocyclic compounds for inhibition of inhibitors of apoptosis |
AU2013361694B2 (en) | 2012-12-20 | 2017-10-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as HDM2 inhibitors |
WO2014100071A2 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted pyrrolopyrimidines as hdm2 inhibitors |
EP2752191A1 (en) | 2013-01-07 | 2014-07-09 | Sanofi | Compositions and methods using hdm2 antagonist and mek inhibitor |
GB201311910D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel Compounds |
NL2011274C2 (en) | 2013-08-06 | 2015-02-09 | Illumicare Ip B V 51 | Groundbreaking platform technology for specific binding to necrotic cells. |
CN105121407B (zh) | 2013-02-28 | 2017-07-18 | 美国安进公司 | 用于治疗癌症的苯甲酸衍生物mdm2抑制剂 |
MX2015012427A (es) | 2013-03-14 | 2016-01-12 | Amgen Inc | Compuestos de morfolinona de acido heteroarilo como inhibidores mdm2 para el tratamiento de cancer. |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
US9637518B2 (en) | 2013-07-12 | 2017-05-02 | Bristol-Myers Squibb Company | IAP antagonists |
JP2017507964A (ja) * | 2014-03-13 | 2017-03-23 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | エストロゲン受容体モジュレーターを用いた治療的組合せ |
MX2016013563A (es) | 2014-04-14 | 2017-05-09 | Arvinas Inc | Moduladores de la proteolisis basados en imida y metodos de uso asociados. |
US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
TW201613916A (en) | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
US20160022642A1 (en) | 2014-07-25 | 2016-01-28 | Yale University | Compounds Useful for Promoting Protein Degradation and Methods Using Same |
US10071164B2 (en) * | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
MX2017004246A (es) * | 2014-10-03 | 2017-05-19 | Conagen Inc | Edulcorantes no caloricos y metodos para sintetizar. |
US9845291B2 (en) * | 2014-12-18 | 2017-12-19 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
WO2016105518A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
US20170327469A1 (en) | 2015-01-20 | 2017-11-16 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
KR20220029783A (ko) | 2015-01-20 | 2022-03-08 | 아비나스 오퍼레이션스, 인코포레이티드 | 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법 |
GB201504314D0 (en) | 2015-03-13 | 2015-04-29 | Univ Dundee | Small molecules |
WO2016149668A1 (en) | 2015-03-18 | 2016-09-22 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
EP3302482A4 (en) | 2015-06-05 | 2018-12-19 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
EP3319944A4 (en) | 2015-07-10 | 2019-04-24 | Arvinas, Inc. | MDM2-BASED PROTEASE MODULATORS AND METHODS OF USE THEREOF |
WO2017011590A1 (en) | 2015-07-13 | 2017-01-19 | Arvinas, Inc. | Alanine-based modulators of proteolysis and associated methods of use |
EP3331905B1 (en) | 2015-08-06 | 2022-10-05 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
WO2017030814A1 (en) | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
GB201516243D0 (en) | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
AU2016349781A1 (en) | 2015-11-02 | 2018-05-10 | Yale University | Proteolysis targeting chimera compounds and methods of preparing and using same |
US20190091227A1 (en) | 2016-03-15 | 2019-03-28 | Merrimack Pharmaceuticals, Inc. | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody |
EP3429996A4 (en) | 2016-03-16 | 2020-02-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | SMALL MOLECULES DIRECTED AGAINST CEREBLON TO IMPROVE THE FUNCTION OF T EFFECTOR LYMPHOCYTES |
US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
WO2017185036A1 (en) | 2016-04-22 | 2017-10-26 | Dana Farber Cancer Institute, Inc. | Bifunctional molecules for degradation of egfr and methods of use |
CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
EP3512842B1 (en) | 2016-09-15 | 2024-01-17 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
JP7009466B2 (ja) * | 2016-10-11 | 2022-02-10 | アルビナス・オペレーションズ・インコーポレイテッド | アンドロゲン受容体の標的分解のための化合物および方法 |
AU2017367872B2 (en) | 2016-11-01 | 2022-03-31 | Arvinas, Inc. | Tau-protein targeting protacs and associated methods of use |
WO2018098280A1 (en) | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use |
RU2750484C2 (ru) | 2016-12-01 | 2021-06-28 | Эрвинэс Оперейшнс, Инк. | Производные тетрагидронафталина и тетрагидроизохинолина в качестве разрушителей эстрогенового рецептора |
EP3559006A4 (en) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES |
CA3047586A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas Operations, Inc. | Egfr proteolysis targeting chimeric molecules and associated methods of use |
WO2018119448A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
KR20230140606A (ko) | 2017-01-26 | 2023-10-06 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 단백질 분해 조절제 및 관련 사용 방법 |
CA3050309A1 (en) | 2017-01-31 | 2018-08-09 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
JP2022546471A (ja) | 2019-08-26 | 2022-11-04 | アルビナス・オペレーションズ・インコーポレイテッド | エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体を用いて乳癌を治療する方法 |
DK3835298T3 (da) | 2019-12-12 | 2024-07-29 | Accutar Biotechnology Inc | Nye chromanderivater med østrogenreceptornedbrydende aktivitet og anvendelser heraf |
CN113816927B (zh) | 2021-11-23 | 2022-02-25 | 苏州国匡医药科技有限公司 | 一种arv-471中间体的制备方法 |
-
2017
- 2017-12-01 RU RU2020106142A patent/RU2750484C2/ru active
- 2017-12-01 FI FIEP20150584.9T patent/FI3689868T3/fi active
- 2017-12-01 CN CN201780085150.9A patent/CN110291087B/zh active Active
- 2017-12-01 HR HRP20231537TT patent/HRP20231537T1/hr unknown
- 2017-12-01 EP EP17875354.7A patent/EP3548483A4/en active Pending
- 2017-12-01 JP JP2019529568A patent/JP6957620B2/ja active Active
- 2017-12-01 KR KR1020197019065A patent/KR102674902B1/ko active IP Right Grant
- 2017-12-01 IL IL266842A patent/IL266842B/en unknown
- 2017-12-01 BR BR112019011200-6A patent/BR112019011200B1/pt active IP Right Grant
- 2017-12-01 CA CA3042968A patent/CA3042968C/en active Active
- 2017-12-01 CN CN202210386845.3A patent/CN114656452B/zh active Active
- 2017-12-01 RS RS20231227A patent/RS64976B1/sr unknown
- 2017-12-01 CN CN202010214256.8A patent/CN111454248A/zh active Pending
- 2017-12-01 AU AU2017366693A patent/AU2017366693B2/en active Active
- 2017-12-01 LT LTEP20150584.9T patent/LT3689868T/lt unknown
- 2017-12-01 KR KR1020247014021A patent/KR20240063185A/ko active Search and Examination
- 2017-12-01 IL IL297717A patent/IL297717A/en unknown
- 2017-12-01 US US15/829,541 patent/US10647698B2/en active Active
- 2017-12-01 SI SI201731464T patent/SI3689868T1/sl unknown
- 2017-12-01 DK DK20150584.9T patent/DK3689868T3/da active
- 2017-12-01 ES ES20150584T patent/ES2967404T3/es active Active
- 2017-12-01 MX MX2019006402A patent/MX2019006402A/es unknown
- 2017-12-01 HU HUE20150584A patent/HUE064609T2/hu unknown
- 2017-12-01 KR KR1020207004766A patent/KR102173464B1/ko active IP Right Grant
- 2017-12-01 WO PCT/US2017/064283 patent/WO2018102725A1/en active Application Filing
- 2017-12-01 PT PT201505849T patent/PT3689868T/pt unknown
- 2017-12-01 PL PL20150584.9T patent/PL3689868T3/pl unknown
- 2017-12-01 EP EP20150584.9A patent/EP3689868B1/en active Active
-
2019
- 2019-05-31 MX MX2022010583A patent/MX2022010583A/es unknown
- 2019-06-28 CO CONC2019/0007091A patent/CO2019007091A2/es unknown
-
2020
- 2020-01-16 US US16/744,414 patent/US10899742B1/en active Active
- 2020-02-06 IL IL272527A patent/IL272527B/en unknown
- 2020-02-28 JP JP2020033150A patent/JP6972211B2/ja active Active
- 2020-03-11 AU AU2020201793A patent/AU2020201793B2/en active Active
- 2020-06-01 US US16/889,490 patent/US11104666B2/en active Active
- 2020-07-17 US US16/932,072 patent/US11597720B2/en active Active
-
2021
- 2021-06-25 US US17/359,424 patent/US20220388984A1/en active Pending
- 2021-06-27 IL IL284424A patent/IL284424B2/en unknown
- 2021-06-30 AU AU2021204549A patent/AU2021204549B2/en active Active
- 2021-07-08 JP JP2021113371A patent/JP7160497B2/ja active Active
- 2021-10-06 JP JP2021164951A patent/JP2022023103A/ja not_active Withdrawn
- 2021-10-25 AU AU2021257895A patent/AU2021257895A1/en not_active Abandoned
-
2022
- 2022-11-02 JP JP2022176319A patent/JP2023021211A/ja active Pending
- 2022-11-28 US US18/070,408 patent/US20240076281A1/en not_active Abandoned
-
2024
- 2024-03-05 AU AU2024201437A patent/AU2024201437A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL284424B (en) | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists | |
ZA201805573B (en) | Selective estrogen receptor degraders and uses thereof | |
HK1247199A1 (zh) | 雌激素受體調節劑及其用途 | |
IL266353A (en) | Steroids and their protein conjugates | |
IL285318A (en) | Estrogen receptor modulators | |
HK1248683A1 (zh) | 雜環雌激素受體調節劑及其用途 | |
HK1258851A1 (zh) | 四氫萘雌激素受體調節劑及其用途 | |
IL247252A0 (en) | History of isoquinoline and its use | |
HK1258886A1 (zh) | T細胞受體及其用途 | |
HK1252202A1 (zh) | 部署裝置及相關的組件和方法 | |
ZA201900113B (en) | Ethynyl derivatives | |
GB2546327B (en) | Security cowl and fixing | |
HK1253294A1 (zh) | 阿片受體調節劑及其用途 | |
IL261055A (en) | Derivatives of tetrahydroisoquinoline | |
GB2550927B (en) | Repositionable self-adhesive closed-cell solid-foam insulation material | |
GB201500597D0 (en) | DAP wallpaper (Design and Print Wallpaper) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
G170 | Re-publication after modification of scope of protection [patent] |